Skip to content

Clinical trial for predicting menstrual period

Clinical trial for predicting menstrual period -Open-label study- - Clinical trial for predicting menstrual period -Open-label study-

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000055649
Enrollment
30
Registered
2024-09-29
Start date
2024-10-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adult

Interventions

The test product is used daily from 7 days before the expected start of menstruation until the onset of menstruation. Perform 2 cycles.

Sponsors

Miura Clinic, Medical Corporation Kanonkai
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) Subjects of women aged 18 to 55 (2) Subjects who are menstruating and aware of discharge just before menstruation (3) Subjects who recieved sufficient explanation about the purpose and consent, voluntarily volunteered to participate after understanding it well, and agreef to participate in the tset in wriring

Exclusion criteria

Exclusion criteria: (1) Subjects with a history of diabetes, liver disease, renal disease, gastrointestinal disease, heart disease, respiratory disease, peripheral vascular disease, or other serious disease (2) Subjects who have undergone surgery on the digestive organs (3) Subjects with abnormal liver function and renal function test values (4) Subjects with diseases currently being treated (5) Subjects who are allergic to foods and drugs (6) Subjects with anemia symptoms (7) Subjects with a diagnosis of endometrial disease (8) Subjects with excessive irregular bleeding (9) Subjects with a history of mental disease (10) Women undergoing infertility treatment and those who have been diagnosed with polycystic ovary syndrome (11) Use of hormonal contraceptives, use of hormone replacement therapy, fertility drugs, artificial insemination, IVF, ICSI Those who are undergoing other medical treatments, such as adjuvant fertility therapy (12) Subjects less than 1 year postpartum (13) Subjects wishing to become pregnant while participating in this study, pregnant (including those who may be pregnant) or lactating female subjects (14) Subjects or a close family member who works for Cranebio Co., Ltd., Unicharm Co., Ltd., or their affiliates. (15) Subjects who play intense sports and subjects who are on a diet (16) Subjects with extremely irregular eating habits (17) Subjects who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the test period (18) Subjects who are continuously receiving medical treatment (including OTC and prescription drugs) (19) Subjects taking pills for menstrual regulation (20) Subjects who drink more than 60 g of average daily pure alcohol (21) Subjects who smoke an average of 21 or more cigarettes a day (22) and (23) are listed in the "Other related infrmation" column.

Design outcomes

Primary

MeasureTime frame
Measurement of protein in the discharge Results of the survey

Countries

Japan

Contacts

Public ContactMakoto Terashima

Oneness Support Co., Ltd. Clinical Trial Division

mterashima@oneness-sup.co.jp06-4801-8917

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026